Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

BACKGROUND: Treatment with tumour necrosis factor inhibitors (TNF-i) plus methotrexate (MTX), but not MTX monotherapy alone, inhibits joint damage progression even at higher levels of disease activity. Such disassociation of disease activity and structural damage has not been shown for biological ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Avila, José C Martinez, Aletaha, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329225/
https://www.ncbi.nlm.nih.gov/pubmed/22121130
http://dx.doi.org/10.1136/annrheumdis-2011-200395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329225/
https://www.ncbi.nlm.nih.gov/pubmed/22121130
http://dx.doi.org/10.1136/annrheumdis-2011-200395

Ejemplares similares